STOCK TITAN
  1. Home
  2. News
  3. NKGN

NKGen Biotech, Inc. - $NKGN STOCK NEWS

Welcome to our dedicated page for NKGen Biotech news (Ticker: $NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NKGen Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NKGen Biotech's position in the market.

News
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
Rhea-AI Summary

NKGen Biotech, Inc. (NKGN) received FDA clearance for its SNK01 NK cell therapy in Parkinson's disease, advancing its neurodegenerative disease program. The Phase 1/2a clinical trial is set to commence in 2H 2024, with SNK01 showing promising potential in addressing Parkinson's disease through enhanced cytotoxicity and activating receptor expression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
clinical trial
-
News
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
Rhea-AI Summary
NKGen Biotech presented updated data on their SNK01 NK cell therapy for neurodegenerative diseases, showcasing positive results in improving cognitive function and reducing neuroinflammation in Alzheimer's patients. The therapy also demonstrated potential applications beyond Alzheimer's, with promising outcomes in Parkinson's disease. The company plans to initiate Phase 2 trials for advanced Alzheimer's and Phase 1 trials for Parkinson's disease in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.69%
Tags
none
-
News
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
NKGen Biotech, a clinical-stage biotechnology company, will present an interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells at the 2024 ASCO Annual Meeting. The study focuses on patients with advanced solid tumors without lymphodepletion. The ePublication will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
none
News
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
Rhea-AI Summary
NKGen Biotech, Inc. announced that Paul Y. Song, MD, will present details on the NK cell therapy in neurodegenerative disease, review preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Phase 1 clinical trial of SNK01 in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit. The presentation will focus on enhancing natural killer cells to combat diseased cells and discuss the potential of NK cell therapy in treating neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.6%
Tags
conferences
-
News
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
Rhea-AI Summary
NKGen Biotech, Inc. secures $5 million in funding to support its neurodegenerative and oncology clinical programs. The company remains on track with its Alzheimer's Phase 2 trial and anticipates Parkinson's Phase 1/2a trial initiation. Dr. Paul Y. Song, Chairman and CEO, expresses confidence in the company's future prospects and strategic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
-
News
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
Rhea-AI Summary
NKGen Biotech, Inc. presents positive Phase 1 trial data on SNK01 autologous NK cell therapy for Alzheimer's disease at Tau2024 Global Conference. The data show improvements in cognitive function, CSF, and plasma Tau proteins, with no adverse events reported. The trial demonstrated potential clinical activity in AD patients, with promising results on biomarkers and cognitive scores.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
clinical trial
News
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
Rhea-AI Summary
NKGen Biotech, Inc. announces the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease. The data will be presented at the Tau2024 Global Conference, showcasing the beneficial effect on Tau proteins and cognitive function in Alzheimer's disease subjects treated with Expanded Non-Genetically Modified Autologous Natural Killer Cells (SNK01).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
-
News
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease
Rhea-AI Summary
NKGen Biotech, Inc. (Nasdaq: NKGN) announced positive results from the Phase 1 dose-escalation safety trial of SNK01, a non-genetically modified NK cell product, showing improvement in neuroinflammation and cognitive function in patients with Alzheimer's Disease. The company has dosed the first patient in its Phase 1/2a trial to evaluate the safety and efficacy of SNK01 in moderate AD, with plans for an interim data readout in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.42%
Tags
clinical trial
-
News
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
Rhea-AI Summary
NKGen Biotech Inc. (Nasdaq: NKGN) has received FDA IND clearance in October 2023 and CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients. The SNK01 program aims to evaluate the safety, tolerability, and efficacy of SNK01 natural killer cell therapy for the treatment of patients with moderate Alzheimer’s Disease. The Phase 1/2a trial of SNK01 in moderate Alzheimer’s disease patients officially opened with the first patient enrolled in December 2023. The company is optimistic about demonstrating more pronounced cognitive benefits and a greater decrease in neuroinflammation. Data from a Phase 1, 3 + 3 dose-escalation trial of SNK01 in patients with AD showed that SNK01 was well tolerated and appeared to have a positive effect on brain protein aggregates and neuroinflammation without any related serious adverse effects observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.73%
Tags
clinical trial
News
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
NKGen Biotech Inc. (NKGN) announced positive results from its SNK01 Phase I autologous clinical program for Alzheimer’s Disease, with improvements in neuroinflammation and cognitive function. The company also provided updates on its SNK02 Phase I allogeneic clinical program, including preliminary solid tumor data readout and IND filing for Parkinson’s Disease in 1Q24. NKGen revealed its third quarter financial results, showcasing a cash position of $8.8 million, R&D and G&A expenses, and a net loss of $33.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
earnings
Stock NKGN logo
NKGen Biotech, Inc.

Nasdaq:NKGN

NKGN Rankings

#4996 Ranked by Market Cap
#4245 Ranked by Stock Gains
N/A Ranked by Dividends

NKGN Stock Data

30.37M
7.30M
60.12%
17.6%
2.81%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SANTA ANA

About NKGN

graf industrial corp is a blank check company. the company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. it intends to focus on industrial companies. it focuses on diversified industrial manufacturing, technology, distribution and service businesses, in the united states and canada.